aspirin has been researched along with bivalirudin in 57 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (19.30) | 18.2507 |
| 2000's | 24 (42.11) | 29.6817 |
| 2010's | 20 (35.09) | 24.3611 |
| 2020's | 2 (3.51) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cannon, CP; Fuchs, J | 1 |
| Bonan, R; Lespérance, J; Pérez-Villa, F; Shabani, F; Théroux, P; Waters, D | 1 |
| Alving, BM; Barr, CF; Gomez, ER; Hamelink, JK; Jackson, MR; Reid, TJ; Tang, DB | 1 |
| Dawson, A; Eisner, J; Findlen, K; Fox, I; Hanson, D; Levin, E; Loynds, P; Mant, T; Maraganore, J; Wagner, J | 1 |
| Adelman, B; Braunwald, E; Cannon, CP; Eddings, K; Fox, I; George, D; Loscalzo, J; Maraganore, JM; McAllister, A; Selwyn, AP | 1 |
| Hirsh, J; Turpie, AG; Weitz, JI | 1 |
| Adelman, B; Adgey, AA; Aylward, PE; Brown, MA; Collins, R; French, JK; Frey, MJ; Hillis, WS; Maraganore, J; Nair, R; Shalev, Y; White, HD | 1 |
| Bentley, R; Bostwick, JS; Dunwiddie, CT; Kasiewski, CJ; Leadley, RJ; McVey, MJ; Perrone, MH; White, FJ | 1 |
| Aylward, P; Ellis, CJ; French, JK; White, HD | 1 |
| Topol, EJ | 1 |
| Honye, J; Kanmatsuse, K; Saito, S | 1 |
| Chauhan, A; More, RS; Qasim, A | 1 |
| Bassand, JP | 1 |
| Bittl, JA; Chaitman, BR; Feit, F; Kimball, W; Topol, EJ | 1 |
| Julian, D | 1 |
| Aylward, PE; French, JK; Gao, W; Krucoff, MW; White, HD; Wong, CK | 1 |
| Manda, SO | 1 |
| Moliterno, DJ; Saw, J | 1 |
| Brener, SJ; Lincoff, AM; Moliterno, DJ; Steinhubl, SR; Topol, EJ; Wolski, KE | 1 |
| Berger, P; Grines, C; Harrington, RA; Ohman, EM; Popma, JJ; Weitz, JI | 1 |
| Bhatt, DL; Duffy, B | 1 |
| French, JK; Gao, W; Raffel, OC; Stewart, RA; White, HD; Wong, CK | 1 |
| Henry, I; Henry, M; Hugel, M; Polydorou, A | 1 |
| Kwa, AT; Rogers, JH | 1 |
| Brodie, BR | 1 |
| Casterella, PJ; Tcheng, JE | 1 |
| Jennings, LK; Saucedo, JF | 1 |
| Schneider, DJ; Sobel, BE | 1 |
| Cohen, M; Giugliano, R; Granger, CB; Gurbel, PA; Hoekstra, J; Hollander, JE; Manoukian, SV; Pollack, CV; Saucedo, JF | 1 |
| Buerke, M; Carter, JM; Hauroeder, B; Maegdefessel, L; Michel, T; Peetz, D; Reindl, I; Schlitt, A; Schubert, S; Werdan, K | 1 |
| Bergman, G; Feldman, DN; Minutello, RM; Wong, SC | 1 |
| Gibson, CM; Hollander, JE; Pollack, CV | 1 |
| Eberli, FR; Roffi, M | 1 |
| Bett, N; Juneja, M; Ray, MJ; Walters, DL | 1 |
| Wessely, R | 1 |
| Aylward, PE; Benatar, J; French, JK; Gao, W; Stewart, RA; White, HD; Wong, CK | 1 |
| Aïssaoui, N; Danchin, N | 1 |
| El-Atat, F; Jakkulla, M; Karajgikar, R; Kini, A; Kodali, V; Mares, A; Sarkar, K; Sharma, S | 1 |
| Moliterno, DJ | 1 |
| Aylward, PE; French, JK; Gao, W; Stewart, RA; White, HD; Wong, CK | 1 |
| Basra, SS; Lakkis, NM; Tsai, P | 1 |
| Ghosn, S; Sheikh-Taha, M | 1 |
| Bhatt, DL | 1 |
| Aslam, R; Ducrocq, N; Gerard, A; Kimmoun, A; Levy, B; Perez, P; Thivilier, C | 1 |
| Gupta, K; Singh, D; Vacek, JL | 1 |
| Byrne, RA; Kastrati, A; Laugwitz, KL; Ndrepepa, G; Neumann, FJ; Pache, J; Pöhler, A; Richardt, G; Schulz, S | 1 |
| Alexander, KP; Li, S; Magid, DJ; Peterson, ED; Roe, MT; Ting, HH; Wang, TY | 1 |
| Baber, U; Badimon, JJ; Crippa, M; Giannarelli, C; Mehran, R; Rodriguez, D; Sartori, S; Tewar, MP; Vorchheimer, DA; Zafar, MU | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
| Généreux, P; Kirtane, AJ; Madhavan, MV; Mehran, R; Stone, GW; Witzenbichler, B; Xu, K | 1 |
| Cacciavillani, L; Calabrò, P; Cavallini, C; De Luca, L; De Servi, S; Gonzini, L; Leonardi, S; Mauro, C; Musumeci, G; Savonitto, S | 1 |
| Clemmensen, P; Engstrøm, T; Helqvist, S; Holmvang, L; Høfsten, DE; Jørgensen, E; Kelbæk, H; Køber, L; Laursen, PN; Møller-Helgestad, OK; Nepper-Christensen, L; Pedersen, F; Ravkilde, J; Sadjadieh, G; Saunamäki, K; Sørensen, R; Terkelsen, CJ; Tilsted, HH | 1 |
| Cavallari, I; Patti, G | 1 |
| Álvarez-Antón, S; Carballeira, D; Concepción, R; Dejuán-Bitriá, C; Del Castillo, H; Delgado-Calva, FA; López-Soberón, E; Marschall, A; Martí, D; Morales, MJ; Palazuelos, J; Pérez-Guzmán, J | 1 |
| Amran, FS; Becker, RC; Chan, MY; Chaudhary, VK; Chee, YL; Chen, W; Croft, G; de Kleijn, DPV; Gupta, A; Hoffman, M; Iyer, JK; Kini, RM; Koh, CY; Leong, EJE; Li, AWL; Mazlan, MIB; Monroe, DM; Richards, AM; Shih, N; Verma, V; Yap, ES; Yip, CYC | 1 |
21 review(s) available for aspirin and bivalirudin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Advances in antithrombotic therapy: novel agents.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Antithrombins; Aspirin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Design; Drug Therapy, Combination; Enzyme Activation; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Hirudin Therapy; Hirudins; Humans; Lipoproteins; Myocardial Infarction; Myocardial Ischemia; Peptide Fragments; Platelet Aggregation Inhibitors; Postoperative Complications; Protein C; Randomized Controlled Trials as Topic; Recombinant Proteins; Thrombolytic Therapy; Thrombophlebitis; Treatment Outcome | 1995 |
Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Cardiac Catheterization; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Heparin; Hirudin Therapy; Hirudins; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Research Design; Ticlopidine | 1998 |
[Conservative management in patients with acute coronary syndrome].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins; Humans; Peptide Fragments; Recombinant Proteins | 1999 |
Failed thrombolysis in myocardial infarction.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clinical Trials as Topic; Electrocardiography; Fibrinolytic Agents; Hirudin Therapy; Hirudins; Humans; Immunoglobulin Fab Fragments; Monitoring, Physiologic; Myocardial Infarction; Peptide Fragments; Plasminogen Activators; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Streptokinase; Thrombolytic Therapy; Time Factors | 2000 |
Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-track revascularization in unstable coronary artery disease.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clinical Trials as Topic; Combined Modality Therapy; Diabetes Complications; Drug Therapy, Combination; Eptifibatide; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Hirudin Therapy; Hirudins; Humans; Immunoglobulin Fab Fragments; Myocardial Revascularization; Oligosaccharides; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Randomized Controlled Trials as Topic; Recombinant Proteins; Risk Factors; Thrombocytopenia; Thrombosis; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Contemporary use of antiplatelet therapies in percutaneous coronary interventions.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Disease; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Stents; Ticlopidine | 2003 |
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Comorbidity; Coronary Restenosis; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Peptide Fragments; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Stents; Thrombophilia; Ticlopidine; Tirofiban; Tyrosine | 2004 |
Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Contraindications; Coronary Restenosis; Coronary Stenosis; Drug Therapy, Combination; Evidence-Based Medicine; Fibrinolytic Agents; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Practice Guidelines as Topic; Pyridines; Recombinant Proteins; Risk Assessment; Stents; Ticlopidine | 2004 |
Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clinical Trials as Topic; Clopidogrel; Eptifibatide; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Recombinant Proteins; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Enoxaparin; Eptifibatide; Fibrinolytic Agents; Heart Conduction System; Hemorrhage; Heparin; Hirudins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Risk Factors; Ticlopidine | 2008 |
Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical da
Topics: American Heart Association; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Drug-Eluting Stents; Hirudins; Humans; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Pyridines; Recombinant Proteins; Societies, Medical; Thrombolytic Therapy; Ticlopidine; United States | 2008 |
Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Hirudins; Humans; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Ticlopidine | 2008 |
Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion.
Topics: Acute Coronary Syndrome; Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Emergency Treatment; Evidence-Based Medicine; Fibrinolytic Agents; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Practice Guidelines as Topic; Prasugrel Hydrochloride; Recombinant Proteins; Risk Assessment; Stents; Thiophenes; Thrombosis; Ticlopidine | 2008 |
Hospitals with and without percutaneous coronary intervention capability: considerations for treating acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Emergency Service, Hospital; Enoxaparin; Fondaparinux; Health Services Accessibility; Hirudins; Humans; Peptide Fragments; Platelet Aggregation Inhibitors; Polysaccharides; Recombinant Proteins; Ticlopidine; Triage; United States | 2009 |
Diabetes and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Enoxaparin; Hirudins; Humans; Hypoglycemic Agents; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Thrombosis; Ticlopidine | 2009 |
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease Management; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Kidney Diseases; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine; Uremia | 2011 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2014 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
Clinical effects with inhibition of multiple coagulative pathways in patients admitted for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Blood Coagulation Factors; Fondaparinux; Hirudins; Humans; Peptide Fragments; Platelet Aggregation Inhibitors; Recombinant Proteins | 2018 |
17 trial(s) available for aspirin and bivalirudin
| Article | Year |
|---|---|
Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hirudin Therapy; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Peptide Fragments; Pilot Projects; Recombinant Proteins; Thrombin | 1995 |
Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction.
Topics: Aspirin; Cardiac Catheterization; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Heparin; Hirudin Therapy; Hirudins; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Recombinant Proteins; Streptokinase; Survival Rate; Thrombin; Vascular Patency | 1995 |
Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Evaluation; Drug Tolerance; Hemostasis; Hirudins; Humans; Infusions, Intravenous; Male; Middle Aged; Peptide Fragments; Recombinant Proteins; Thrombin | 1993 |
Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease.
Topics: Amino Acid Sequence; Aspirin; Blood Coagulation; Blood Coagulation Tests; Cardiac Catheterization; Coronary Disease; Female; Heparin; Hirudin Therapy; Hirudins; Humans; Male; Middle Aged; Molecular Sequence Data; Peptide Fragments; Recombinant Proteins; Thrombin | 1993 |
Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators.
Topics: Analysis of Variance; Antithrombins; Aspirin; Cardiac Catheterization; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heparin; Hirudin Therapy; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Recombinant Proteins; Recurrence; Streptokinase; Thrombolytic Therapy | 1997 |
Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO-2) Study.
Topics: Aged; Antithrombins; Aspirin; Female; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Recombinant Proteins; Streptokinase; Thrombolytic Therapy | 1998 |
Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion.
Topics: Acute Disease; Anticoagulants; Aspirin; Coronary Angiography; Coronary Circulation; Double-Blind Method; Electrocardiography; Endpoint Determination; Female; Fibrinolytic Agents; Heparin; Hirudins; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Reperfusion; Peptide Fragments; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Streptokinase; Thrombolytic Therapy; Vascular Patency | 2002 |
A Bayesian ordinal model for heterogeneity in a multi-centre myocardial infarction clinical trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Bayes Theorem; Clinical Trials, Phase I as Topic; Coronary Angiography; Female; Fibrinolytic Agents; Hirudins; Humans; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptide Fragments; Recombinant Proteins; Regression Analysis; Streptokinase; Treatment Outcome | 2002 |
Initial Q waves accompanying ST-segment elevation at presentation of acute myocardial infarction and 30-day mortality in patients given streptokinase therapy: an analysis from HERO-2.
Topics: Aged; Anticoagulants; Aspirin; Drug Therapy, Combination; Electrocardiography; Female; Heparin; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Predictive Value of Tests; Recombinant Proteins; Streptokinase; Thrombolytic Therapy | 2006 |
Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis. Results of an in-vitro study.
Topics: Anticoagulants; Aspirin; Cardiac Catheterization; Enoxaparin; Eptifibatide; Erythrocytes; Fibrin; Fibrinolytic Agents; Heparin; Hirudins; Humans; In Vitro Techniques; Male; Microscopy, Electron, Scanning; Peptide Fragments; Peptides; Perfusion; Platelet Aggregation Inhibitors; Recombinant Proteins; Thrombosis | 2008 |
A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagu
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biomarkers; Blood Coagulation; CD40 Ligand; Clopidogrel; Drug Therapy, Combination; Female; Fibrinogen; Heparin; Hirudins; Humans; Lipoproteins; Male; Membrane Glycoproteins; Middle Aged; Monocytes; Peptide Fragments; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prothrombin; Recombinant Proteins; Thromboplastin; Thrombosis; Ticlopidine; Treatment Outcome | 2009 |
Prognostic value of lead V1 ST elevation during acute inferior myocardial infarction.
Topics: Aged; Anterior Wall Myocardial Infarction; Anticoagulants; Aspirin; Bundle-Branch Block; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Hirudins; Humans; Male; Middle Aged; Peptide Fragments; Predictive Value of Tests; Prognosis; Recombinant Proteins; Risk Factors; Streptokinase | 2010 |
A randomized pilot trial for aggressive therapeutic approaches in aspirin-resistant patients undergoing percutaneous coronary intervention.
Topics: Adult; Angioplasty, Balloon, Coronary; Antithrombins; Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Hirudins; Humans; Male; Middle Aged; Peptide Fragments; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Ticlopidine | 2011 |
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab wi
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; United States | 2011 |
The prognostic meaning of the full spectrum of aVR ST-segment changes in acute myocardial infarction.
Topics: Aged; Antithrombins; Aspirin; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Prognosis; Recombinant Proteins; Streptokinase | 2012 |
Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin.
Topics: Adenosine; Adult; Antithrombins; Aspirin; Blood Coagulation; Clopidogrel; Cross-Over Studies; Drug Synergism; Female; Healthy Volunteers; Hirudins; Humans; Male; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Recombinant Proteins; Thrombelastography; Ticagrelor; Ticlopidine | 2014 |
Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial.
Topics: Aged; Antithrombins; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Heparin; Hirudins; Humans; Male; Middle Aged; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Postoperative Complications; Prospective Studies; Recombinant Proteins; Secondary Prevention; ST Elevation Myocardial Infarction; Survival Rate; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2017 |
19 other study(ies) available for aspirin and bivalirudin
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Inhibition of platelet deposition by combined hirulog and aspirin in a rat carotid endarterectomy model.
Topics: Animals; Aspirin; Blood Platelets; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endarterectomy, Carotid; Hirudin Therapy; Hirudins; Male; Peptide Fragments; Postoperative Complications; Random Allocation; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Thrombin; Thrombosis | 1995 |
Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Topics: Adenosine Diphosphate; Animals; Aspirin; Bleeding Time; Collagen; Coronary Thrombosis; Dogs; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Hemostasis; Heparin; Hirudin Therapy; Hirudins; Male; Partial Thromboplastin Time; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Prothrombin; Prothrombin Time; Recombinant Proteins; Recurrence; Safety; Thrombin; Thrombolytic Therapy; Tissue Plasminogen Activator | 1997 |
Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Female; Follow-Up Studies; Heparin; Hirudin Therapy; Hirudins; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptide Fragments; Randomized Controlled Trials as Topic; Recombinant Proteins; Survival Rate | 2001 |
Absolute and relative truth in clinical trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Heparin; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Randomized Controlled Trials as Topic; Recombinant Proteins; Reproducibility of Results | 2002 |
Endovascular treatment of a renal artery stenosis: techniques, indications, results. Role of embolic protection devices (part 2).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Catheterization; Clopidogrel; Embolism; Fibrinolytic Agents; Heparin; Hirudins; Humans; Peptide Fragments; Platelet Aggregation Inhibitors; Recombinant Proteins; Renal Artery Obstruction; Ticlopidine | 2007 |
What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Heparin; Hirudins; Humans; Myocardial Infarction; Patient Selection; Peptide Fragments; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Research Design; Stents; Thrombin; Thrombosis; Ticlopidine; Treatment Outcome | 2008 |
Lack of early augmentation of platelet reactivity after coronary intervention in patients treated with bivalirudin.
Topics: Adenosine Diphosphate; Angina Pectoris; Anticoagulants; Aspirin; Cardiac Catheterization; Clopidogrel; Elective Surgical Procedures; Hemostatics; Hirudins; Humans; Peptide Fragments; Platelet Activation; Platelet Aggregation Inhibitors; Postoperative Period; Recombinant Proteins; Thrombin; Ticlopidine; Time Factors | 2009 |
Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Embolism; Eptifibatide; Female; Follow-Up Studies; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Registries; Regression Analysis; Retrospective Studies; Thrombosis; Ticlopidine; Treatment Outcome | 2009 |
Initial experience with an institutional bridging protocol for patients with recent coronary stent implantation requiring discontinuation of dual antiplatelet therapy resulting from urgent surgery.
Topics: Antithrombins; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Hirudins; Humans; Peptide Fragments; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Recombinant Proteins; Stents; Surgical Procedures, Operative; Ticlopidine; Time Factors | 2011 |
Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study.
Topics: Aged; Alabama; Antithrombins; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Elective Surgical Procedures; Female; Hemorrhage; Hirudins; Humans; Incidence; Infusions, Intravenous; Injections, Intravenous; Ischemia; Male; Middle Aged; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recombinant Proteins; Retrospective Studies; Severity of Illness Index; Thrombosis; Ticlopidine | 2012 |
Bleeding complications during percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Ticlopidine | 2004 |
Critical illness-related corticosteroid insufficiency in cardiogenic shock.
Topics: Adrenal Insufficiency; Adrenergic alpha-Agonists; Adult; Anti-Inflammatory Agents; Antihypertensive Agents; Aspirin; Bisoprolol; Critical Illness; Epinephrine; Fibrinolytic Agents; Hirudins; Humans; Hydrocortisone; Male; Peptide Fragments; Piperazines; Prasugrel Hydrochloride; Ramipril; Recombinant Proteins; Shock, Cardiogenic; Thiophenes; Treatment Outcome | 2013 |
Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Logistic Models; Male; Middle Aged; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Proportional Hazards Models; Recombinant Proteins; Risk Factors; Stents; Ticlopidine | 2014 |
The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Early Medical Intervention; Female; Guideline Adherence; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Patient Transfer; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Pyridines; Recombinant Proteins; Retrospective Studies; Ticlopidine; Time-to-Treatment | 2014 |
Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions: insights from the EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitaliz
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cross-Sectional Studies; Female; Heparin; Hirudins; Humans; Italy; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Recombinant Proteins; Registries | 2017 |
Relation of Bleeding Events to Mortality in Patients With ST-Segment Elevation Myocardial Infarction Treated by Percutaneous Coronary Intervention (a DANAMI-3 Substudy).
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Creatinine; Female; Heparin; Hirudins; Humans; Incidence; Male; Middle Aged; Mortality; Multivariate Analysis; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Prognosis; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Recombinant Proteins; Sex Factors; ST Elevation Myocardial Infarction; Time-to-Treatment | 2018 |
Impact of Anemia on the Risk of Bleeding Following Percutaneous Coronary Interventions in Patients ≥75 Years of Age.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Angina, Unstable; Anticoagulants; Antithrombins; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Artery Disease; Drug-Eluting Stents; Female; Gastrointestinal Hemorrhage; Hemorrhage; Heparin; Hirudins; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Hemorrhage; Prasugrel Hydrochloride; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Risk Assessment; Stents; Ticagrelor; Urologic Diseases | 2020 |
Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors.
Topics: Amblyomma; Animals; Antibodies; Anticoagulants; Antidotes; Antithrombins; Aspirin; Drug Development; Drug Discovery; Female; Fibrinolytic Agents; Gene Library; Heparin; Hirudins; Humans; Male; Peptide Fragments; Percutaneous Coronary Intervention; Proteomics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Swine; Thrombin; Thrombosis; Ticks; Transcriptome | 2021 |